Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 171

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 171
---
 PIPE Financing and also excludes the following:

| • |     | 36,166 shares of our common stock issuable upon the exercise of warrants to purchase common stock that were 
 outstanding as of September 30, 2024, with an exercise price of $7.29 per share;                            |

| • |     | 5,256,229 shares of our common stock issuable upon the exercise of stock options to purchase common stock that 
 were outstanding as of September 30, 2024, with a weighted average exercise price of $10.99 per share;         |

| • |     | 2,426,493 shares of our common stock issuable upon the exercise of prefunded warrants to purchase common stock                                     
 that were sold in our September 2022 private placement and were outstanding as of September 30, 2024, with an exercise price of $0.0001 per share; |

- 114 -

| • |     | 110,000 shares of common stock reserved for issuance pursuant to future awards under our 2023 Inducement Equity 
 Incentive Plan;                                                                                                 |

| • |     | 678,482 shares of common stock reserved for issuance pursuant to future awards under our 2021 Plan, as well as        
 any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and |

| • |     | 844,059 shares of common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock                                
 Purchase Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan. |

- 115 -

THE ADC PROGRAMS Overview We are a precision oncology company making bold choices in applying technology to efficiently deliver improved therapies for people living with difficult-to-treat cancers. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, successfully taking product candidates from the clinic to approval, launch, and commercialization. We recently entered into an intellectual property license agreement (the “License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. See the section entitled “ THE PIPE FINANCING AND LICENSE AGREEMENT